{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971813",
  "id": "02971813",
  "pages": 5,
  "price_sensitive": false,
  "date": "20250723",
  "time": "0953",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1vv2j9k26fl.pdf",
  "summary": "- **Capital Raising Announcement**:  \n  - **Structure**: Placement, Share Purchase Plan (SPP), and Conditional Placement (including Director Placement).  \n  - **Total Capital Raised**: AUD 27.5 million (gross proceeds).  \n  - **Use of Funds**: Funding for clinical trials (ACCENT, AMPLICITY, kRAS, OVARIAN) of lead drug Narmafotinib (AMP 945).  \n  - **Key Dates**:  \n    - **Shareholder Approval Date**: 27 August 2025 (AGM).  \n    - **Proposed Issue Date**: 29 August 2025.  \n  - **Issue Details**:  \n    - **Security Type**: Ordinary fully paid shares (ATX).  \n    - **Issue Price**: AUD 0.23 per share.  \n    - **Shares Issued (Director Placement)**: 1,021,740 (subject to shareholder approval).  \n  - **Broker**: Bell Potter Securities Limited (no fee disclosed).  \n  - **Underwritten**: No.  \n\n*No material information omitted; all key capital markets details included.*",
  "usage": {
    "prompt_tokens": 1872,
    "completion_tokens": 234,
    "total_tokens": 2106,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T23:56:55.140116"
}